Jun 12, 2019 / 09:00PM GMT
Salveen Jaswal Richter - Goldman Sachs Group Inc., Research Division - VP
Good afternoon. Thanks, everyone, for joining us. I'm Salveen Richter, one of the biotech technology analysts at Goldman Sachs. And we're pleased to have the team from Moderna here today. We have Stéphane Bancel, CEO; and Lorence Kim, CFO.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group Inc., Research Division - VPSo maybe to start, just given your recent IPO, could you just provide us with a brief overview of the company, the mRNA technology and your modality approach to drug development?
Stéphane Bancel - Moderna, Inc. - CEO & Director
Okay. Good. So thank you so much for having us today. So Moderna, as many of you know, are using messenger RNA to make medicine inside people's body. We believe this is a new class of medicine that provides a very large product opportunity, because to further the protein coding in the human genome are not [drug-able] using recombinant technology. Because it's a
Trustpilot
